These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32044516)

  • 1. Single-step synthesis and in vitro anti-mycobacterial activity of novel nitrofurantoin analogues.
    Zuma NH; Smit FJ; Seldon R; Aucamp J; Jordaan A; Warner DF; N'Da DD
    Bioorg Chem; 2020 Mar; 96():103587. PubMed ID: 32044516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and In vitro antituberculosis activity of 2(5H)-Furanone derivatives.
    Ngwane AH; Panayides JL; Chouteau F; Macingwana L; Viljoen A; Baker B; Madikane E; de Kock C; Wiesner L; Chibale K; Parkinson CJ; Mmutlane EM; van Helden P; Wiid I
    IUBMB Life; 2016 Aug; 68(8):612-20. PubMed ID: 27346745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
    Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
    Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel C-3-(N-alkyl-aryl)-aminomethyl rifamycin SV derivatives exhibit activity against rifampicin-resistant Mycobacterium tuberculosis RpoB
    Zloh M; Gupta M; Parish T; Brucoli F
    Eur J Med Chem; 2021 Dec; 225():113734. PubMed ID: 34418786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid derivatives and their anti-tubercular activity.
    Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
    Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversed isoniazids: Design, synthesis and evaluation against Mycobacterium tuberculosis.
    Kumar M; Singh K; Ngwane AH; Hamzabegovic F; Abate G; Baker B; Wiid I; Hoft DF; Ruminski P; Chibale K
    Bioorg Med Chem; 2018 Feb; 26(4):833-844. PubMed ID: 29373270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and antimycobacterial activity of novel ciprofloxacin derivatives.
    Cilliers P; Seldon R; Smit FJ; Aucamp J; Jordaan A; Warner DF; N'Da DD
    Chem Biol Drug Des; 2019 Aug; 94(2):1518-1536. PubMed ID: 31033220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and in vitro anti-mycobacterial evaluation of gatifloxacin-1H-1,2,3-triazole-isatin hybrids.
    Xu Z; Zhang S; Song X; Qiang M; Lv Z
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3643-3646. PubMed ID: 28720502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of new 2-aminothiophenes against Mycobacterium tuberculosis.
    Thanna S; Knudson SE; Grzegorzewicz A; Kapil S; Goins CM; Ronning DR; Jackson M; Slayden RA; Sucheck SJ
    Org Biomol Chem; 2016 Jul; 14(25):6119-6133. PubMed ID: 27251120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of oxime-functionalized nitrofuranylamides as novel antitubercular agents.
    Fan YL; Wu JB; Ke X; Huang ZP
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3064-3066. PubMed ID: 30119957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action.
    Vosátka R; Krátký M; Švarcová M; Janoušek J; Stolaříková J; Madacki J; Huszár S; Mikušová K; Korduláková J; Trejtnar F; Vinšová J
    Eur J Med Chem; 2018 May; 151():824-835. PubMed ID: 29679902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore.
    Salunke SB; Azad AK; Kapuriya NP; Balada-Llasat JM; Pancholi P; Schlesinger LS; Chen CS
    Bioorg Med Chem; 2015 May; 23(9):1935-43. PubMed ID: 25818768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
    Gao F; Chen Z; Ma L; Fan Y; Chen L; Lu G
    Eur J Med Chem; 2019 Oct; 180():648-655. PubMed ID: 31352245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derivatives of 3-isoxazolecarboxylic acid esters: a potent and selective compound class against replicating and nonreplicating Mycobacterium tuberculosis.
    Lilienkampf A; Pieroni M; Franzblau SG; Bishai WR; Kozikowski AP
    Curr Top Med Chem; 2012; 12(7):729-34. PubMed ID: 22283815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.